Abstract: Disclosed are methods and compositions for treating infections caused by DNA viruses, including symptoms of the infections. The infections can be co-infections of the DNA viruses and other viruses. The methods, for example, can include administering pharmaceutical compositions comprising pipendoxifene disclosed herein to a patient in need.

Abstract: Disclosed herein are broad-spectrum antiviral compounds that can prevent or treat disorders related to RNA viral infections. Also disclosed are methods and composition for treating RNA viral infections, including symptoms of the RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising one or more of the compounds disclosed herein to a patient in need.

Abstract: Disclosed herein are broad-spectrum antiviral compounds that can prevent or treat disorders related to RNA viral infections. Also disclosed are methods and composition for treating RNA viral infections, including symptoms of the RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising one or more of the compounds disclosed herein to a patient in need.

Abstract: Disclosed are methods and compositions for treating infections caused by DNA viruses, including symptoms of the infections. The infections can be co-infections of the DNA viruses and other viruses. The methods, for example, can include administering pharmaceutical compositions comprising pipendoxifene disclosed herein to a patient in need.

Abstract: Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions or analogues thereof to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.

Abstract: Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising Pipendoxifene or analogues thereof (e.g., a compound of Formula (I), Formula (II), or Formula (III)) to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.

Abstract: Disclosed herein include methods, compositions, and kits suitable for use in treatment and/or prevention of RNA viral infections. In some embodiments, the method comprises modulation of host factors related to RNA viral infection using compounds, compositions and kits disclosed herein. There are provided, some embodiments, compounds modulating host factors that govern SARS-CoV-2 replication. Disclosed herein include the use of compounds, compositions and kits disclosed herein to prevent and/or treat SARS-CoV-2 infection, for example by modulating the SARS-CoV-2 life cycle.

Abstract: Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions or analogues thereof to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.